$-0.03
(Market cap
$14 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
22,594,000
10 Years Aggregate
CFO
€-262.26 Mln
EBITDA
€-256.13 Mln
Net Profit
€-288.92 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celyad Oncology SA - ADR
| 6.3 | 18.2 | -16.8 | -71.0 | -63.2 | -55.4 | -- |
|
BSE Sensex*
| -9.2 | -1.6 | 2.8 | -3.7 | 5.8 | 6.0 | 10.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Celyad Oncology SA - ADR
| -86.5 | -53.1 | -25.1 | -42.6 | -57.7 | 142.7 | -67.5 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celyad Oncology SA - ADR
|
0.5 | 14.2 | 0.0 | -40.9 | -- | -170.7 | -- | 0.7 |
| 1,031.7 | 63,631.2 | 8,446.3 | 2,595.8 | 21.8 | 33 | 38.9 | 7.9 | |
| 13.8 | 850.9 | 0.0 | -175.9 | -- | -106.8 | -- | 5.7 | |
| 22.7 | 12,469.9 | 19,427.2 | 937.8 | 9.6 | 5.1 | 12.4 | 0.9 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 2.2 | 248.0 | 2.8 | -49.2 | -86.4 | 764.8 | -- | 20.1 | |
| 4.7 | 1,111.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 40.6 | 2,095.0 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 | |
| 6.3 | 609.7 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.6 |
Shareholding Pattern
View DetailsAbout Celyad Oncology SA - ADR
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic... CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Read more
-
Co-Founder, CFO, Interim CEO & Director
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME
-
Co-Founder, CFO, Interim CEO & Director
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME
-
Headquarters
Mont-Saint-Guibert
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Celyad Oncology SA - ADR
What is the current share price of Celyad Oncology SA - ADR Today?
The share price of Celyad Oncology SA - ADR is $0.52 (NASDAQ) as of 20-Jul-2023 09:30 EDT. Celyad Oncology SA - ADR has given a return of -63.22% in the last 3 years.
What is the current PB & PE ratio of Celyad Oncology SA - ADR?
Since, TTM earnings of Celyad Oncology SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Celyad Oncology SA - ADR?
The 52-week high and low of Celyad Oncology SA - ADR are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of Celyad Oncology SA - ADR?
Celyad Oncology SA - ADR has a market capitalisation of $ 14 Mln as on 20-Jul-2023. As per SEBI classification, it is a company.
Should I invest in Celyad Oncology SA - ADR?
Before investing in Celyad Oncology SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.